Noticias de CSPC Pharmaceutical Group

1093 · HKEX · HKD

10,00 $+1,47 %+0,14 $

Cierre · 6 de octubre de 2026

Últimas noticias

Titulares en el idioma original de la fuente.

Big Pharma Is Pouring Billions Into China’s Biotechs (se abre en una pestaña nueva)
Barrons.com · 14 sept 2026
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight (se abre en una pestaña nueva)
PR Newswire · 1 jun 2026
CSPC’s SYS6051 Trial Approval Adds New Angle To Valuation Story (se abre en una pestaña nueva)
Simply Wall St. · 22 abr 2026
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation (se abre en una pestaña nueva)
PR Newswire · 22 abr 2026
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint (se abre en una pestaña nueva)
PR Newswire · 1 abr 2026
How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story (se abre en una pestaña nueva)
Simply Wall St. · 7 nov 2025
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates (se abre en una pestaña nueva)
GlobeNewswire · 4 nov 2025
How Dual U.S. and China Trial Approvals for SYH2070 Could Shape CSPC (SEHK:1093) Investors' Outlook (se abre en una pestaña nueva)
Simply Wall St. · 13 oct 2025